Welcome to Elusys Therapeutics, Inc.

We are committed to developing new biotherapeutic products that dramatically improve treatment of life-threatening infectious disease.

 

Anthim, an anthrax anti-toxin with life-saving potential, has reached a late stage of development. Elusys has recently signed a contract totaling up to $143 Million to complete the final development, commercial manufacturing and licensure of Anthim. learn more

 

 

 

ANTHIM®
Highly effective in treating anthrax-infected animals, Anthim is in late-stage product development.

learn more >>

 

 

Elusys & Biodefense
Elusys has received a contract totaling up to $143 Million to complete the final development, commercial manufacturing and licensure of Anthim.

learn more >>

 

Anthrax & Bioterrorism
Anthrax remains the number one bioterrorism threat. Development of effective new therapies are essential to
protect Americans.

learn more >>

NEWS

January 11th, 2012
Elusys President/CEO is presenting at the 2012 Biotech Showcase in San Francisco
read more >>

October 24th, 2011
Elusys initiates third clinical safety study of Anthim, a new anthrax treatment; company successfully completes manufacturing at commercial scale
read more >>

Elizabeth Posillico, PhD inducted into NJ’s High Tech Hall of Fame

LEARN MORE ABOUT...

Anthim and Anthrax
See how Anthim prevents cell death from anthrax toxin
view animation >>

Working at Elusys
A dynamic, creative environment to advance your career
learn more >>

Biodefense
Important Information on biodefense and emergency preparedness
learn more >>